Madrigal Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 63 to 83.

The post Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark appeared first on Investor’s Business Daily.